This single-center, single-blind, randomized controlled trial conducted in Pakistan assessed the effects of intravenous vitamin C (IVC) on symptom severity in 350 breast cancer patients (stages IIA–IIIb) undergoing standard treatment. Participants were randomized to receive either 25g/week of IVC or placebo over four weeks. The IVC group showed statistically significant
